Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]
Awaiting development
Reference number: GID-TA11336
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during in late October 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-January 2026.